Shazid Md. Sharker* and Md. Atiqur Rahman Pages 1 - 11 ( 11 )
Most of clinical approved protein-based drugs or under in clinical trial have a profound impact in the treatment of critical diseases. The mammalian eukaryotic cells culture approaches, particularly the CHO (Chinese Hamster Ovary) cells are mainly used in the biopharmaceutical industry for the mass-production of therapeutic protein. Recent advances in CHO cell bioprocessing to yield recombinant proteins and monoclonal antibodies have enabled the expression of quality protein. The developments of cell lines are possible to upgrade specific productivity. As a result, it holds an interesting area for academic as well as industrial researchers around the world. This review will concentrate on the recent progress of the mammalian CHO cells culture technology and the future scope of further development for the mass-production of protein therapeutics.
Therapeutic protein, mammalian cells, CHO cells, protein expression, bio-processing, mass-production
North South University, Department of Pharmaceutical Sciences, Plot # 15, Block # B, Bashundhara R/A, Dhaka-1229, Division of Hematology and Oncology, Mayo Clinic, Scottsdale, Arizona